Fuyuhiko Tamanoi

List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/4416643/publications.pdf Version: 2024-02-01

		36303	27406
122	11,611	51	106
papers	citations	h-index	g-index
124	124	124	14539
all docs	docs citations	times ranked	citing authors

#	Article	IF	CITATIONS
1	Multifunctional Inorganic Nanoparticles for Imaging, Targeting, and Drug Delivery. ACS Nano, 2008, 2, 889-896.	14.6	1,758
2	Biocompatibility, Biodistribution, and Drugâ€Delivery Efficiency of Mesoporous Silica Nanoparticles for Cancer Therapy in Animals. Small, 2010, 6, 1794-1805.	10.0	947
3	Mesoporous Silica Nanoparticles as a Delivery System for Hydrophobic Anticancer Drugs. Small, 2007, 3, 1341-1346.	10.0	927
4	Autonomous in Vitro Anticancer Drug Release from Mesoporous Silica Nanoparticles by pH-Sensitive Nanovalves. Journal of the American Chemical Society, 2010, 132, 12690-12697.	13.7	550
5	Lightâ€Activated Nanoimpellerâ€Controlled Drug Release in Cancer Cells. Small, 2008, 4, 421-426.	10.0	430
6	A tagging-via-substrate technology for detection and proteomics of farnesylated proteins. Proceedings of the National Academy of Sciences of the United States of America, 2004, 101, 12479-12484.	7.1	322
7	Spatial regulation of the exocyst complex by Rho1 GTPase. Nature Cell Biology, 2001, 3, 353-360.	10.3	288
8	Development of mesoporous silica-based nanoparticles with controlled release capability for cancer therapy. Advanced Drug Delivery Reviews, 2015, 95, 40-49.	13.7	228
9	Mesoporous Silica Nanoparticles Facilitate Delivery of siRNA to Shutdown Signaling Pathways in Mammalian Cells. Small, 2010, 6, 1185-1190.	10.0	215
10	Synthesis of Biomoleculeâ€Modified Mesoporous Silica Nanoparticles for Targeted Hydrophobic Drug Delivery to Cancer Cells. Small, 2011, 7, 1816-1826.	10.0	204
11	Small-Molecule Inhibitors of Protein Geranylgeranyltransferase Type I. Journal of the American Chemical Society, 2007, 129, 5843-5845.	13.7	196
12	In vivo tumor suppression efficacy of mesoporous silica nanoparticles-based drug-delivery system: enhanced efficacy by folate modification. Nanomedicine: Nanotechnology, Biology, and Medicine, 2012, 8, 212-220.	3.3	192
13	Loss of the TOR Kinase Tor2 Mimics Nitrogen Starvation and Activates the Sexual Development Pathway in Fission Yeast. Molecular and Cellular Biology, 2007, 27, 3154-3164.	2.3	181
14	Specific Activation of mTORC1 by Rheb C-protein in Vitro Involves Enhanced Recruitment of Its Substrate Protein. Journal of Biological Chemistry, 2009, 284, 12783-12791.	3.4	179
15	Therapeutic intervention based on protein prenylation and associated modifications. Nature Chemical Biology, 2006, 2, 518-528.	8.0	176
16	The Rheb family of GTP-binding proteins. Cellular Signalling, 2004, 16, 1105-1112.	3.6	175
17	Mesoporous Silica Nanoparticles for Cancer Therapy: Energy-Dependent Cellular Uptake and Delivery of Paclitaxel to Cancer Cells. Nanobiotechnology, 2007, 3, 89-95.	1.2	175
18	Inhibitors of ras farnesyltransferases. Trends in Biochemical Sciences, 1993, 18, 349-353.	7.5	167

Γυγυμικό Ταμανοι

#	Article	IF	CITATIONS
19	Protein-gold clusters-capped mesoporous silica nanoparticles for high drug loading, autonomous gemcitabine/doxorubicin co-delivery, and in-vivo tumor imaging. Journal of Controlled Release, 2016, 229, 183-191.	9.9	149
20	Drosophila Rheb GTPase is required for cell cycle progression and cell growth. Journal of Cell Science, 2003, 116, 3601-3610.	2.0	147
21	Neurofibromatosis 2 tumour suppressor schwannomin interacts with Î ² II-spectrin. Nature Genetics, 1998, 18, 354-359.	21.4	145
22	Involvement of Lysosomal Exocytosis in the Excretion of Mesoporous Silica Nanoparticles and Enhancement of the Drug Delivery Effect by Exocytosis Inhibition. Small, 2013, 9, 697-704.	10.0	137
23	Point mutations in TOR confer Rheb-independent growth in fission yeast and nutrient-independent mammalian TOR signaling in mammalian cells. Proceedings of the National Academy of Sciences of the United States of America, 2007, 104, 3514-3519.	7.1	133
24	The Saccharomyces cerevisiae Rheb G-protein Is Involved in Regulating Canavanine Resistance and Arginine Uptake. Journal of Biological Chemistry, 2000, 275, 11198-11206.	3.4	119
25	Twoâ€₽hotonâ€Triggered Drug Delivery via Fluorescent Nanovalves. Small, 2014, 10, 1752-1755.	10.0	106
26	Mutational and functional analysis of the neurofibromatosis type 1 (NF1) gene. Human Genetics, 1996, 99, 88-92.	3.8	105
27	Identification of Dominant Negative Mutants of Rheb GTPase and Their Use to Implicate the Involvement of Human Rheb in the Activation of p70S6K. Journal of Biological Chemistry, 2003, 278, 39921-39930.	3.4	105
28	Mevalonate Pathway and Human Cancers. Current Molecular Pharmacology, 2017, 10, 77-85.	1.5	103
29	Mesostructured Silica for Optical Functionality, Nanomachines, and Drug Delivery. Journal of the American Ceramic Society, 2009, 92, s2-s10.	3.8	101
30	Chick chorioallantoic membrane assay as an in vivo model to study the effect of nanoparticle-based anticancer drugs in ovarian cancer. Scientific Reports, 2018, 8, 8524.	3.3	101
31	Cdk inhibitors, roscovitine and olomoucine, synergize with farnesyltransferase inhibitor (FTI) to induce efficient apoptosis of human cancer cell lines. Oncogene, 2000, 19, 3059-3068.	5.9	96
32	Twoâ€₽hotonâ€Triggered Drug Delivery in Cancer Cells Using Nanoimpellers. Angewandte Chemie - International Edition, 2013, 52, 13813-13817.	13.8	94
33	Identification of novel single amino acid changes that result in hyperactivation of the unique GTPase, Rheb, in fission yeast. Molecular Microbiology, 2005, 58, 1074-1086.	2.5	83
34	Fission yeast TORC1 regulates phosphorylation of ribosomal S6 proteins in response to nutrients and its activity is inhibited by rapamycin. Journal of Cell Science, 2010, 123, 777-786.	2.0	82
35	Biodegradable Oxamideâ€Phenyleneâ€Based Mesoporous Organosilica Nanoparticles with Unprecedented Drug Payloads for Delivery in Cells. Chemistry - A European Journal, 2016, 22, 14806-14811.	3.3	81
36	Inhibitors of Protein Geranylgeranyltransferase I and Rab Geranylgeranyltransferase Identified from a Library of Allenoate-derived Compounds. Journal of Biological Chemistry, 2008, 283, 9571-9579.	3.4	79

Γυγυμικό Ταμανοί

#	Article	IF	CITATIONS
37	Hyaluronic acid conjugated nanoparticle delivery of siRNA against TWIST reduces tumor burden and enhances sensitivity to cisplatin in ovarian cancer. Nanomedicine: Nanotechnology, Biology, and Medicine, 2018, 14, 1381-1394.	3.3	75
38	<i>In vivo</i> antitumor effect of a novel inhibitor of protein geranylgeranyltransferase-I. Molecular Cancer Therapeutics, 2009, 8, 1218-1226.	4.1	72
39	Silica nanoparticles as a delivery system for nucleic acid-based reagents. Journal of Materials Chemistry, 2009, 19, 6308.	6.7	72
40	Loss of tuberous sclerosis complex 1 (Tsc1) expression results in increased Rheb/S6K pathway signaling important for astrocyte cell size regulation. Glia, 2004, 47, 180-188.	4.9	69
41	Nanoparticle delivery of siRNA against TWIST to reduce drug resistance and tumor growth in ovarian cancer models. Nanomedicine: Nanotechnology, Biology, and Medicine, 2017, 13, 965-976.	3.3	67
42	Functional Nanovalves on Protein-Coated Nanoparticles for In vitro and In vivo Controlled Drug Delivery. Small, 2015, 11, 319-328.	10.0	65
43	Psk1, an AGC kinase family member in fission yeast, is directly phosphorylated and controlled by TORC1 and functions as S6 kinase. Journal of Cell Science, 2012, 125, 5840-5849.	2.0	64
44	Recent progress in the study of the Rheb family GTPases. Cellular Signalling, 2014, 26, 1950-1957.	3.6	64
45	A novel approach to tag and identify geranylgeranylated proteins. Electrophoresis, 2009, 30, 3598-3606.	2.4	63
46	Failure to farnesylate Rheb protein contributes to the enrichment of G0/G1 phase cells in the Schizosaccharomyces pombe farnesyltransferase mutant. Molecular Microbiology, 2001, 41, 1339-1347.	2.5	62
47	Development of mesoporous silica nanomaterials as a vehicle for anticancer drug delivery. Therapeutic Delivery, 2012, 3, 389-404.	2.2	62
48	Activating mutations of TOR (target of rapamycin). Genes To Cells, 2011, 16, 141-151.	1.2	60
49	Increased Rheb-TOR signaling enhances sensitivity of the whole organism to oxidative stress. Journal of Cell Science, 2006, 119, 4285-4292.	2.0	59
50	Farnesylated proteins and cell cycle progression. Journal of Cellular Biochemistry, 2001, 84, 64-70.	2.6	56
51	Farnesyltransferase inhibitors reverse altered growth and distribution of actin filaments in Tsc-deficient cells via inhibition of both rapamycin-sensitive and -insensitive pathways. Molecular Cancer Therapeutics, 2005, 4, 918-926.	4.1	55
52	Ras Signaling in Yeast. Genes and Cancer, 2011, 2, 210-215.	1.9	55
53	Significance of filamin A in mTORC2 function in glioblastoma. Molecular Cancer, 2015, 14, 127.	19.2	52
54	Mesoporous silica nanoparticle delivery of chemically modified siRNA against TWIST1 leads to reduced tumor burden. Nanomedicine: Nanotechnology, Biology, and Medicine, 2015, 11, 1657-1666.	3.3	51

Γυγυμικό Ταμανοι

#	Article	IF	CITATIONS
55	Tailoring the biodegradability of porous silicon nanoparticles. Journal of Biomedical Materials Research - Part A, 2012, 100A, 3416-3421.	4.0	46
56	Periodic Mesoporous Organosilica Nanoparticles with Controlled Morphologies and High Drug/Dye Loadings for Multicargo Delivery in Cancer Cells. Chemistry - A European Journal, 2016, 22, 9607-9615.	3.3	46
57	The TSC/Rheb/TOR Signaling Pathway in Fission Yeast and Mammalian Cells: Temperature Sensitive and Constitutive Active Mutants of TOR. Cell Cycle, 2007, 6, 1692-1695.	2.6	41
58	The Tsc/Rheb signaling pathway controls basic amino acid uptake via the Cat1 permease in fission yeast. Molecular Genetics and Genomics, 2008, 279, 441-450.	2.1	41
59	PAK1 Kinase Promotes Cell Motility and Invasiveness through CRK-II Serine Phosphorylation in Non-Small Cell Lung Cancer Cells. PLoS ONE, 2012, 7, e42012.	2.5	41
60	Hybrid Mesoporous Silica Nanoparticles with pHâ€Operated and Complementary Hâ€Bonding Caps as an Autonomous Drugâ€Đelivery System. Chemistry - A European Journal, 2014, 20, 9372-9380.	3.3	40
61	Biodegradability of Disulfide-Organosilica Nanoparticles Evaluated by Soft X-ray Photoelectron Spectroscopy: Cancer Therapy Implications. ACS Applied Nano Materials, 2019, 2, 479-488.	5.0	39
62	Designing Mesoporous Silica Nanoparticles to Overcome Biological Barriers by Incorporating Targeting and Endosomal Escape. ACS Applied Materials & Interfaces, 2021, 13, 9656-9666.	8.0	39
63	Characterization of the Rhebâ€mTOR Signaling Pathway in Mammalian Cells: Constitutive Active Mutants of Rheb and mTOR. Methods in Enzymology, 2008, 438, 307-320.	1.0	38
64	Patient Derived Chicken Egg Tumor Model (PDcE Model): Current Status and Critical Issues. Cells, 2019, 8, 440.	4.1	38
65	Cytosolic and mitochondrial ROS production resulted in apoptosis induction in breast cancer cells treated with Crocin: The role of FOXO3a, PTEN and AKT signaling. Biochemical Pharmacology, 2020, 177, 113999.	4.4	37
66	Protein Farnesylation Is Critical for Maintaining Normal Cell Morphology and Canavanine Resistance in Schizosaccharomyces pombe. Journal of Biological Chemistry, 2000, 275, 429-438.	3.4	35
67	Increasing the length of progerin's isoprenyl anchor does not worsen bone disease or survival in mice with Hutchinson-Gilford progeria syndrome. Journal of Lipid Research, 2009, 50, 126-134.	4.2	33
68	Biodegradable Periodic Mesoporous Organosilica (BPMO) Loaded with Daunorubicin: A Promising Nanoparticleâ€Based Anticancer Drug. ChemMedChem, 2020, 15, 593-599.	3.2	33
69	Rheb G-Proteins and the Activation of mTORC1. The Enzymes, 2010, 27, 39-56.	1.7	29
70	Destruction of tumor mass by gadolinium-loaded nanoparticles irradiated with monochromatic X-rays: Implications for the Auger therapy. Scientific Reports, 2019, 9, 13275.	3.3	29
71	In vitro and in vivo effects of geranylgeranyltransferase I inhibitor P61A6 on non-small cell lung cancer cells. BMC Cancer, 2013, 13, 198.	2.6	28
72	A novel inhibitor of farnesyltransferase with a zinc site recognition moiety and a farnesyl group. Bioorganic and Medicinal Chemistry Letters, 2017, 27, 3862-3866.	2.2	28

Γυγυμικό Ταμανοί

#	Article	IF	CITATIONS
73	Characterization of the geranylgeranyl transferase type I fromSchizosaccharomyces pombe. Molecular Microbiology, 1998, 29, 1357-1367.	2.5	26
74	Significance of KRAS/PAK1/Crk pathway in non-small cell lung cancer oncogenesis. BMC Cancer, 2015, 15, 381.	2.6	26
75	Continuous spectroscopic measurements of photo-stimulated release of molecules by nanomachines in a single living cell. Nanoscale, 2012, 4, 3482.	5.6	24
76	Fission yeast arrestin-related trafficking adaptor, Arn1/Any1, is ubiquitinated by Pub1 E3 ligase and regulates endocytosis of Cat1 amino acid transporter. Biology Open, 2014, 3, 542-552.	1.2	24
77	Rheb Protein Binds CAD (Carbamoyl-phosphate Synthetase 2, Aspartate Transcarbamoylase, and) Tj ETQq1 1 0.7		
77	Localization and Carbamoyl-phosphate Synthetase (CPSase) Activity. Journal of Biological Chemistry, 2015, 290, 1096-1105.	3.4	24
78	Overview of Studies Regarding Mesoporous Silica Nanomaterials and Their Biomedical Application. The Enzymes, 2018, 43, 1-10.	1.7	24
79	Characterization of Rheb functions using yeast and mammalian systems. Methods in Enzymology, 2001, 333, 217-231.	1.0	21
80	Prenylation of RAS and Inhibitors of Prenyltransferases. , 1996, , 95-137.		21
81	A novel metal-Chelating inhibitor of protein farnesyltransferase. Bioorganic and Medicinal Chemistry Letters, 2003, 13, 1523-1526.	2.2	20
82	Recent Development to Explore the Use of Biodegradable Periodic Mesoporous Organosilica (BPMO) Nanomaterials for Cancer Therapy. Pharmaceutics, 2020, 12, 890.	4.5	19
83	Identification and Characterization of Mechanism of Action of P61-E7, a Novel Phosphine Catalysis-Based Inhibitor of Geranylgeranyltransferase-I. PLoS ONE, 2011, 6, e26135.	2.5	17
84	Anticancer Effect and Molecular Targets of Saffron Carotenoids. The Enzymes, 2014, 36, 57-86.	1.7	17
85	Miniaturization of thiol-organosilica nanoparticles induced by an anionic surfactant. Journal of Colloid and Interface Science, 2018, 526, 51-62.	9.4	16
86	Relationship between the glutathione-responsive degradability of thiol-organosilica nanoparticles and the chemical structures. Journal of Materials Research, 2019, 34, 1266-1278.	2.6	15
87	Construction of Boronophenylalanine-Loaded Biodegradable Periodic Mesoporous Organosilica Nanoparticles for BNCT Cancer Therapy. International Journal of Molecular Sciences, 2021, 22, 2251.	4.1	15
88	The Ras Superfamily G-Proteins. The Enzymes, 2013, 33 Pt A, 1-14.	1.7	13
89	Drug Release from Threeâ€Dimensional Cubic Mesoporous Silica Nanoparticles Controlled by Nanoimpellers. Zeitschrift Fur Anorganische Und Allgemeine Chemie, 2014, 640, 588-594.	1.2	13
90	Recent Progress in Developing Small Molecule Inhibitors Designed to Interfere with Ras Membrane Association. The Enzymes, 2013, 34 Pt. B, 181-200.	1.7	12

Γυγυμικό Ταμανοι

#	Article	IF	CITATIONS
91	How Phytochemicals Prevent Chemical Carcinogens and/or Suppress Tumor Growth?. The Enzymes, 2015, 37, 1-42.	1.7	12
92	In vitro delivery of calcium ions by nanogated mesoporous silica nanoparticles to induce cancer cellular apoptosis. Molecular Systems Design and Engineering, 2017, 2, 384-392.	3.4	12
93	Isolation and characterization of the primary epithelial breast cancer cells and the adjacent normal epithelial cells from Iranian women's breast cancer tumors. Cytotechnology, 2018, 70, 625-639.	1.6	12
94	Advances in the development of farnesyltransferase inhibitors: Substrate recognition by protein farnesyltransferase. Journal of Cellular Biochemistry, 1997, 67, 12-19.	2.6	10
95	Conservation of the Tsc/Rheb/TORC1/S6K/S6 Signaling in Fission Yeast. The Enzymes, 2010, 28, 167-187.	1.7	10
96	Studies on the Exposure of Gadolinium Containing Nanoparticles with Monochromatic X-rays Drive Advances in Radiation Therapy. Nanomaterials, 2020, 10, 1341.	4.1	10
97	lodine containing porous organosilica nanoparticles trigger tumor spheroids destruction upon monochromatic X-ray irradiation: DNA breaks and K-edge energy X-ray. Scientific Reports, 2021, 11, 14192.	3.3	10
98	Nanoformulation of Geranylgeranyltransferase-I Inhibitors for Cancer Therapy: Liposomal Encapsulation and pH-Dependent Delivery to Cancer Cells. PLoS ONE, 2015, 10, e0137595.	2.5	9
99	Reducing particle size of biodegradable nanomaterial for efficient curcumin loading. Journal of Materials Science, 2021, 56, 3713-3722.	3.7	9
100	An oncogenic mutant of RHEB, RHEB Y35N, exhibits an altered interaction with BRAF resulting in cancer transformation. BMC Cancer, 2018, 18, 69.	2.6	8
101	The CAM Model for CIC-DUX4 Sarcoma and Its Potential Use for Precision Medicine. Cells, 2021, 10, 2613.	4.1	8
102	A Two-Hybrid Approach to Identify Inhibitors of the RAS–RAF Interaction. The Enzymes, 2013, 33 Pt A, 213-248.	1.7	7
103	Recent excitements in the study of the CAM assay. The Enzymes, 2019, 46, 1-9.	1.7	7
104	Chemical Biology/ Chemical Genetics/ Chemical Genomics: Importance of Chemical Library. Chem-Bio Informatics Journal, 2007, 7, 49-68.	0.3	6
105	Exploiting Enzyme Alterations in Cancer for Drug Activation, Drug Delivery, and Nanotherapy. The Enzymes, 2017, 42, 153-172.	1.7	5
106	Facile synthesis of biodegradable mesoporous functionalized-organosilica nanoparticles for enhancing the anti-cancer efficiency of cordycepin. Microporous and Mesoporous Materials, 2021, 315, 110913.	4.4	4
107	Fiber-Optic Based Laser Wakefield Accelerated Electron Beams and Potential Applications in Radiotherapy Cancer Treatments. Photonics, 2022, 9, 403.	2.0	4
108	Using Drosophila and Yeast Genetics to Investigate a Role for the Rheb GTPase in Cell Growth. Methods in Enzymology, 2006, 407, 443-454.	1.0	3

Γυγυηικό Ταμανοι

#	Article	IF	CITATIONS
109	Nanoparticle-Based Delivery of siRNA and miRNA for Cancer Therapy. The Enzymes, 2012, , 185-203.	1.7	3
110	Tumor Targeting and Tumor Growth Inhibition Capability of Mesoporous Silica Nanoparticles in Mouse Models. The Enzymes, 2018, 44, 61-82.	1.7	3
111	Anticancer Drug Delivery Capability of Biodegradable PMO in the Chicken Egg Tumor Model. The Enzymes, 2018, 44, 103-116.	1.7	3
112	Magnetic Nanoparticles and Alternating Magnetic Field for Cancer Therapy. Fundamental Biomedical Technologies, 2021, , 165-179.	0.2	1
113	Ras Family G-Proteins in Saccharomyces Cerevisiae and Schizosaccharomyces Pombe. , 2006, , 227-256.		1
114	Genetic Analysis of FTase and GGTase I and Natural Product Farnesyltransferase Inhibitors. , 0, , 145-157.		1
115	Tumor Accumulation of PIP-Based KRAS Inhibitor KR12 Evaluated by the Use of a Simple, Versatile Chicken Egg Tumor Model. Cancers, 2022, 14, 951.	3.7	1
116	Effects of farnesyltransferase inhibitors on cell cycle progression of human cancer cells. Gene Function & Disease, 2001, 2, 99-107.	0.3	0
117	Clobal Analysis of Prenylated Proteins by the Use of a Tagging via Substrate Approach. The Enzymes, 2011, , 195-206.	1.7	0
118	Introduction. The Enzymes, 2014, 36, 1-6.	1.7	0
119	Frontispiece: Biodegradable Oxamideâ€Phenyleneâ€Based Mesoporous Organosilica Nanoparticles with Unprecedented Drug Payloads for Delivery in Cells. Chemistry - A European Journal, 2016, 22, .	3.3	0
120	GTP-Binding Protein Rheb. , 2016, , 1-6.		0
121	In vivo Tumor Suppression Efficacy of Mesoporous Silica Nanoparticle-Based Drug Delivery System: Enhanced Efficacy by Folate Modification. , 2017, , 215-234.		Ο
122	GTP-Binding Protein Rheb. , 2018, , 2288-2293.		0